Feedback / Questions
BT-0267 - Brenig Therap
https://www.prnewswire.com/news-releases/brenig-therapeutics-presented-new-data-for-the-best-in-class-lrrk2-inhibitor-targeting-parkinsons-disease-at-the-acs-spring-2024-conference-302091628.html
Mar 18, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next